DSIP — clinical evidence
Assessed outcomes with certainty ratings, contributing trials and the reasoning for each rating.
§3Clinical evidence
§3.1Alcohol use disorder
Anchor outcome. Drinks per drinking day.
Effect as recorded. Small historical reports in withdrawal syndromes; not assessable; —.[1,2]
Certainty. Very low certainty —
Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.
Full evidence extract for alcohol use disorder · Indication assessment
§3.2Cognitive performance and neuroprotection
Anchor outcome. Domain-specific cognitive test scores.
Effect as recorded. No assessable evidence identified; —.[2,3]
Certainty. Very low certainty —
Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.
Full evidence extract for cognitive performance and neuroprotection · Indication assessment
§3.3Sleep initiation and maintenance disorders
Anchor outcome. Sleep-onset latency.
Effect as recorded. Small historical studies reported inconsistent effects on sleep architecture; the effect that gave the peptide its name has not been reliably reproduced; inconsistent.[3]
Certainty. Very low certainty The Institute assesses this as very low certainty and notes specifically that the balance of the historical evidence does not support a somnogenic effect.
Contributing trials. DSIP-HIST-SLEEP. Full structured abstracts are published for each.
Full evidence extract for sleep initiation and maintenance disorders · Indication assessment
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6 · PMID 20143256
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi:10.1136/bmj.n71 · PMID 33782057
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.